- Home
- PMEC vs PTN Comparison
PMEC vs PTN Comparison
Compare PMEC & PTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMEC
- PTN
- Stock Information
- Founded
- PMEC 1984
- PTN 1986
- Country
- PMEC Singapore
- PTN United States
- Employees
- PMEC 2744
- PTN N/A
- Industry
- PMEC
- PTN Biotechnology: Pharmaceutical Preparations
- Sector
- PMEC
- PTN Health Care
- Exchange
- PMEC Nasdaq
- PTN Nasdaq
- Market Cap
- PMEC 26.2M
- PTN 25.4M
- IPO Year
- PMEC 2023
- PTN 1993
- Fundamental
- Price
- PMEC $0.69
- PTN $1.00
- Analyst Decision
- PMEC
- PTN Strong Buy
- Analyst Count
- PMEC 0
- PTN 1
- Target Price
- PMEC N/A
- PTN $7.00
- AVG Volume (30 Days)
- PMEC 323.0K
- PTN 1.7M
- Earning Date
- PMEC 12-31-2024
- PTN 02-13-2025
- Dividend Yield
- PMEC N/A
- PTN N/A
- EPS Growth
- PMEC N/A
- PTN N/A
- EPS
- PMEC N/A
- PTN N/A
- Revenue
- PMEC $72,524,000.00
- PTN $350,000.00
- Revenue This Year
- PMEC N/A
- PTN N/A
- Revenue Next Year
- PMEC N/A
- PTN N/A
- P/E Ratio
- PMEC N/A
- PTN N/A
- Revenue Growth
- PMEC 5.07
- PTN N/A
- 52 Week Low
- PMEC $0.49
- PTN $0.68
- 52 Week High
- PMEC $4.15
- PTN $3.99
- Technical
- Relative Strength Index (RSI)
- PMEC 46.18
- PTN 50.51
- Support Level
- PMEC $0.69
- PTN $0.99
- Resistance Level
- PMEC $0.74
- PTN $1.08
- Average True Range (ATR)
- PMEC 0.08
- PTN 0.14
- MACD
- PMEC -0.00
- PTN 0.01
- Stochastic Oscillator
- PMEC 6.64
- PTN 35.59
About PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About PTN Palatin Technologies Inc.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.